However, their combination with sulfonylureas (SUs) increases the risk of severe hypoglycemia, necessitating careful dose adjustments, especially in older adults and those with impaired renal function [22]
Strengths Weaknesses Opportunities Threats Novo Nordisk Offers: Rybelsus (oral semaglutide) for type 2 diabetes, Ozempic (injectable), Wegovy (higher-dose semaglutide for obesity), among its portfolio
Nanoformulation for enhanced drug delivery and better patient compliance
Our focus keyphrase, GLP1 weight loss vs surgery and diet , will guide this exploration, helping you determine the most effective strategy for your unique goals
Availability depends on provider evaluation, state participation, pharmacy requirements, and clinical eligibility